Bank of America
NRSNW icon

Bank of America’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History

Bank of America’s Portfolio NRSNW Stock Details NRSNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200
Closed -$22 – 8157
2023
Q3 		$22 Buy
200
+100
+100% +$18 ﹤0.01% 7566
2023
Q2 		$16 Buy
+100
New +$32 ﹤0.01% 7529

Other funds holding NRSNW

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Bank of America's NRSNW Position: Q4 2023 in Review

Bank of America sold out of NeuroSense Therapeutics Warrant (NRSNW) in Q4 2023, closing a stake of 200 shares — an estimated $22 sold.

Bank of America first reported a position in NRSNW in Q2 2023 and held it in 2 quarters. The position peaked at $22 in Q3 2023. 3 funds tracked by Wall St. Rank hold NRSNW as of Q4 2023.

  • Bank of America reported no remaining NeuroSense Therapeutics Warrant position as of Q4 2023 after selling out during the quarter.
  • Bank of America sold 200 NeuroSense Therapeutics Warrant shares in Q4 2023, an estimated $22.
  • Bank of America first reported a position in NeuroSense Therapeutics Warrant in Q2 2023 and held it in 2 quarters.
  • Bank of America's NeuroSense Therapeutics Warrant position peaked at $22 in Q3 2023.
  • 3 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q4 2023.

Based on Bank of America's 13F filing for Q4 2023, filed 14 Feb 2024.